← All trials
NCT05967130
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2023
- Primary completion
- Jan 1, 2024
- Completion date
- Jul 1, 2024
- First posted
- Aug 1, 2023
- Last posted
- Aug 1, 2023
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shahid Beheshti University of Medical SciencesLead sponsor
- Shahid Beheshti University of Medical SciencesReponsible party - principal investigator
- Shahid Beheshti University of Medical SciencesSponsor investigator
- Azad UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.